Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Radiotherapy Followed by Chemotherapy and Anti-PD-1 Immunotherapy in MSS Rectal Cancer With Resectable Liver/ Pulmonary Metastasis(Miracle-1): A Prospective, Single Arm, Multi-Center, Phase II Clinical Trial

NCT05359393 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT05359393
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05359393 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Radiotherapy Followed by Chemotherapy and Anti-PD-1 Immunotherapy in MSS Rectal Cancer With Resectable Liver/ Pulmonary Metastasis(Miracle-1): A Prospective, Single Arm, Multi-Center, Phase II Clinical Trial
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
December 1, 2022
Completion date
September 1, 2027
Enrollment
52 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced rectal cancer, liver metastasis, microsatellite stable colorectal carcinoma, pulmonary metastasis